Trial
NCT03866317
A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Massachusetts General Hospital
Collaborators
Novartis
Condition
Discoid Lupus Erythematosus
Intervention
Secukinumab
Why stopped
Difficulty recruiting participants
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-09-08